Physician profile
Carolyn Jane Becker
NPI 1255479176
$24,489.56
in general payments reported to CMS, 2019-2025
55 companies · $1,132 in 2025
The $1,132 reported for 2025 was more than what 90% of Clinical Nurse Specialist providers received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,221 · 2022: $12K · 2023: $5,970 · 2024: $2,264 · 2025: $1,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,112 · Consulting Fee: $3,540 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $831 · Travel and Lodging: $679 · Education: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,112.48 |
| Consulting Fee | $3,540.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $831.00 |
| Travel and Lodging | $679.10 |
| Education | $203.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $14,922.23 | 2021-2025 | Opdivo, Opdualag, Augtyro |
| Celgene Corporation | $2,757.83 | 2021-2024 | Reblozyl, Pomalyst |
| Janssen Biotech, INC. | $2,328.37 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Abbvie INC. | $414.90 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $361.11 | 2021-2025 | Enhertu, Imfinzi |
| Novartis Pharmaceuticals Corporation | $333.22 | 2022-2025 | |
| Pfizer INC. | $290.14 | 2021-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $260.47 | 2021-2023 | Epkinly, Imbruvica |
| Merck Sharp & Dohme LLC | $195.49 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Genmab U.S., INC. | $192.26 | 2023-2025 | Epkinly, Tivdak |
| Daiichi Sankyo INC. | $145.65 | 2021-2025 | Enhertu, Datroway |
| Exelixis INC. | $143.97 | 2021-2025 | Cabometyx |
| Genzyme Corporation | $137.62 | 2021-2024 | |
| Eisai INC. | $125.73 | 2022-2025 | |
| Incyte Corporation | $119.57 | 2021-2025 | Jakafi, Monjuvi, Niktimvo |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carolyn Becker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.